Xencor, Inc. (XNCR) Holdings Raised by Virginia Retirement Systems ET AL

Virginia Retirement Systems ET AL boosted its holdings in shares of Xencor, Inc. (NASDAQ:XNCR) by 10.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 76,200 shares of the biopharmaceutical company’s stock after acquiring an additional 6,900 shares during the quarter. Virginia Retirement Systems ET AL owned about 0.16% of Xencor worth $1,747,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of XNCR. Great West Life Assurance Co. Can boosted its position in shares of Xencor by 158.9% during the third quarter. Great West Life Assurance Co. Can now owns 6,526 shares of the biopharmaceutical company’s stock worth $150,000 after buying an additional 4,005 shares during the period. TD Asset Management Inc. boosted its position in shares of Xencor by 20.5% during the third quarter. TD Asset Management Inc. now owns 98,521 shares of the biopharmaceutical company’s stock worth $2,258,000 after buying an additional 16,752 shares during the period. Artal Group S.A. purchased a new position in shares of Xencor during the third quarter worth $2,292,000. Los Angeles Capital Management & Equity Research Inc. purchased a new position in shares of Xencor during the third quarter worth $572,000. Finally, Swiss National Bank boosted its position in shares of Xencor by 5.2% during the third quarter. Swiss National Bank now owns 66,400 shares of the biopharmaceutical company’s stock worth $1,522,000 after buying an additional 3,300 shares during the period. 77.62% of the stock is owned by institutional investors.

Shares of Xencor, Inc. (NASDAQ:XNCR) opened at $22.19 on Wednesday. Xencor, Inc. has a 52 week low of $18.55 and a 52 week high of $29.38.

In other Xencor news, major shareholder John S. Stafford III purchased 24,653 shares of the business’s stock in a transaction on Wednesday, October 25th. The shares were bought at an average cost of $20.01 per share, for a total transaction of $493,306.53. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder John S. Stafford III purchased 50,000 shares of the business’s stock in a transaction on Thursday, November 2nd. The stock was acquired at an average price of $19.58 per share, for a total transaction of $979,000.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 263,105 shares of company stock worth $5,206,858. 4.14% of the stock is owned by insiders.

Several research analysts have recently commented on the company. Canaccord Genuity restated a “buy” rating and set a $36.00 price target on shares of Xencor in a research report on Tuesday, August 8th. ValuEngine upgraded Xencor from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Zacks Investment Research lowered Xencor from a “hold” rating to a “sell” rating in a report on Friday, August 11th. BidaskClub lowered Xencor from a “hold” rating to a “sell” rating in a report on Monday, August 14th. Finally, Cantor Fitzgerald started coverage on Xencor in a report on Wednesday, November 29th. They issued an “overweight” rating and a $33.00 target price for the company. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $30.80.

COPYRIGHT VIOLATION WARNING: “Xencor, Inc. (XNCR) Holdings Raised by Virginia Retirement Systems ET AL” was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The legal version of this news story can be viewed at https://www.com-unik.info/2017/12/06/xencor-inc-xncr-holdings-raised-by-virginia-retirement-systems-et-al.html.

Xencor Profile

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Want to see what other hedge funds are holding XNCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xencor, Inc. (NASDAQ:XNCR).

Institutional Ownership by Quarter for Xencor (NASDAQ:XNCR)

What are top analysts saying about Xencor Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Xencor Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit